Bal Pharma Share Price

Bal Pharma

CMP as on 23-May-22 15:41

₹ 101.65
-2.40 -2.31%

Open

₹ 104.90

Turnover (lac)

₹ 21

Prev. Close

₹ 104.05

Day's Vol (shares)

₹ 20,732

Day's Range (₹)

₹ 101.00
₹ 104.90

CMP as on23-May-22 15:28

₹ 100.45
-2.45 -2.38%

Open

₹ 104.45

Turnover (lac)

₹ 6

Prev. Close

₹ 102.90

Day's Vol (shares)

₹ 2,305

Day's Range

₹ 100.45
₹ 104.55

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 05-Apr-2022 - -
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/04/2022 inter alia to consider and approve allotment of equity shares to the beneficiaries who have exercised the conversion option on the warrants allotted to them on preferential basis. Pursuant to applicable provisions of Chapter V of SEBI (ICDR) Regulations, 2018 and Section 42 of the Companies Act,2013 & Companies (Prospectus and allotment of Securities) Rules, 2014 as amended from time to time and after having received the full consideration amount , the Board of Directors of the Company at its meeting held on today i.e 13.04.2022 has inter alia approved the allotment of 7,50,000 equity shares of Rs.10/- each to the following investor , upon conversion of Warrants allotted to him on preferential basis: Sl No Name of the Investor Category of Investor No of equity shares allotted Distinctive Numbers 01 Mr Shailesh Siroya Promoter 7,50,000 14822373 to 15572372 With this allotment, the paid-up equity share capital of the Company has risen to Rs.15,57,23,720/- divided into 1,55,72,372 equity shares of Rs.10 each (As Per BSE Announcement Dated on 13.04.2022)
Board Meeting - 28-Feb-2022 - -
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2022 inter alia to consider and approve The meeting of Board of Directors of the Company is scheduled to be held on 9.03.2022 i.e on Wednesday to inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd subject to the approval of applicable statutes and shareholders of the Company. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held on 9th March, 2022, has considered and approved the Scheme of Merger (the Scheme) pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, if any, providing for the merger of its wholly owned subsidiary- Golden Drugs Private Limited (Transferor Company) with Bal Pharma Limited (Transferee Company). The Scheme would be implemented subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Bengaluru Bench). The Company will be filing joint application with Honble National Company Law Tribunal (Bengaluru Bench) in due course of time to obtain approval on the scheme as required under the provisions of the Companies Act, 2013. (As Per BSE Announcement dated on 09.03.2022)
Board Meeting - 28-Jan-2022 - -
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 inter alia to consider and approve Unaudited financial results ( standalone & Consolidated ) for the quarter ended 31.12.2021. The Board of Directors of the Company has met to day and inter alia transacted the following business. Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022. (As Per BSE Announcement Dated on 10/02/2022)
Board Meeting - 22-Oct-2021 - -
Quarterly Results The Board of Directors of the Company has met to day and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021. (As Per BSE Announcement Dated 11.11.2021) We are resubmitting the higher resolution , clear and legible financial results of the Company for the quarter and half year ended 30.09.2021. (As Per BSE Announcement dated on 09.12.2021)
Board Meeting - 26-Jul-2021 - -
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2021 ,inter alia, to consider and approve 1. Un audited financial results (Standalone and Consolidated) of the Company for the quarter ended 30.06.2021. 2. allotment of stock options to the employees under Bal Pharma Ltd-Employee Stock Option Scheme -2014. 3. Any other matters relating to Annual General Meeting. Sub : Out come of the Board Meeting. The Board of Directors of the Company has met to day and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2021. Copy of the stand alone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. 2.Approved the grant of 4,16,500 stock options to the employees of the Company under Bal Pharma Ltd - Employee Stock Option Plan -2014. The meeting commenced at 16.30 p.m and concluded at 17.30 on 10.08.2021. (As per BSE Announcement Dated on 10/8/2021)
Board Meeting - 15-Jun-2021 - -
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2021 ,inter alia, to consider and approve Notice is hereby given that the meeting of Board of Directors of the Company is scheduled to be held on 29th June 2021 i.e on Tuesday through video conference/audio visual means. The Board of Directors inter alia will be considering, 1.Approval of Audited financial results (Standalone and Consolidated) of the Company for the financial year ended 31.03.2021. 2. To consider recommendation of Dividend, if any, for the financial year ended 31.03.2021. 3. To consider restructuring of the group Companies 3. To decide on the Book closure and AGM dates. 4. To consider any other matters relating to Annual General Meeting. Bal Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 29, 2021, inter alia, has recommended dividend of Re. 1/- per equity share of Rs. 10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2021. A copy of the Audited financials (Standalone and Consolidated) along with audit reports are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. 3. Decided to convene the 34th Annual General Meeting of the Company on Friday 24th September, 2021, by audio visual means. 5 4.Decided to close the Register of Members and Share Transfer books of the Company from 18th September 2021 to 24th September 2021 (Both days inclusive). 5.The Board considered and authorised Mr.Shailesh Siroya, Managing Director to undertake restructuring process of the group Companies, subject to various legal and taxation aspects. (As Per BSE Announcement Dated on 29.06.2021) Board of Directors of the Company at their meeting held on 29.06.2021 has decided to close the Register of Members and Share Transfer Books of the Company from 18.06.2021 to 24.06.2021 ( Both days inclusive ) to ascertain the entitlement of Dividend and for 34th Annual General Meeting of the Company scheduled to be held on 24.09.2021 i.e on Friday through audio visual means. (As per BSE Announcement Dated on 30/06/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity